Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses.
Sign Up to like & getrecommendations! Published in 2019 at "Cell reports"
DOI: 10.1016/j.celrep.2019.09.009
Abstract: BRAF fusions are detected in numerous neoplasms, but their clinical management remains unresolved. We identified six melanoma lines harboring BRAF fusions representative of the clinical cases reported in the literature. Their unexpected heterogeneous responses to… read more here.
Keywords: genetic heterogeneity; braf fusions; braf; fusion kinases ... See more keywords
Diverse BRAF Gene Fusions Confer Resistance to EGFR-Targeted Therapy via Differential Modulation of BRAF Activity
Sign Up to like & getrecommendations! Published in 2020 at "Molecular Cancer Research"
DOI: 10.1158/1541-7786.mcr-19-0529
Abstract: Fusion genes can be oncogenic drivers in a variety of cancer types and represent potential targets for targeted therapy. The BRAF gene is frequently involved in oncogenic gene fusions, with fusion frequencies of 0.2%–3% throughout… read more here.
Keywords: therapy; braf fusions; fusion; braf ... See more keywords
Targeting rare variants of a pan-cancer target: The landscape of BRAF non-v600 mutations and BRAFfusions from 172,005 adult patients with cancer.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.3113
Abstract: 3113 Background: BRAF is a recognized pan-cancer target, with dabrafenib in combination with trametinib receiving FDA accelerated approval for unresectable metastatic solid tumors with BRAF V600E mutation. BRAF fusions and mutations at codons aside from… read more here.
Keywords: non v600; cancer; braf fusions; braf ... See more keywords